Frontier Zdravlje has received marketing authorisations for Apixaban Frontier and Rivaroxaban Frontier in Croatia, Bulgaria and Romania.

Apixaban Frontier 2.5 mg and 5 mg was authorised in Croatia on 15 July 2026, in Bulgaria on 11 September and in Romania on 25 September. Rivaroxaban Frontier 10 mg, 15 mg and 20 mg was authorised in Croatia on 24 August, in Romania on 7 September and in Bulgaria on 15 September.

The EU decentralised procedures for both products have been completed.